Urinary lysophopholipids are increased in diabetic patients with nephropathy.
暂无分享,去创建一个
S. Hadjadj | J. Schanstra | R. Roussel | J. Bertrand-Michel | P. Gourdy | B. Guerci | J. Halimi | J. Saulnier-Blache | J. Bascands | E. Feigerlová | Aude Dupuy
[1] H. Jun,et al. Blocking lysophosphatidic acid receptor 1 signaling inhibits diabetic nephropathy in db/db mice. , 2017, Kidney international.
[2] M. McCarthy,et al. The Genetic Landscape of Renal Complications in Type 1 Diabetes. , 2017, Journal of the American Society of Nephrology : JASN.
[3] Prasenjit Manna,et al. Mechanistic insight of diabetic nephropathy and its pharmacotherapeutic targets: An update. , 2016, European journal of pharmacology.
[4] J. Schanstra,et al. Increased urinary lysophosphatidic acid in mouse with subtotal nephrectomy: potential involvement in chronic kidney disease , 2016, Journal of Physiology and Biochemistry.
[5] C. Pollock,et al. Increased sphingosine 1‐phosphate mediates inflammation and fibrosis in tubular injury in diabetic nephropathy , 2016, Clinical and Experimental Pharmacology and Physiology.
[6] Guixia Wang,et al. Metabolomic biomarkers in diabetic kidney diseases--A systematic review. , 2015, Journal of diabetes and its complications.
[7] J. Ahmad. Management of diabetic nephropathy: Recent progress and future perspective. , 2015, Diabetes & metabolic syndrome.
[8] Katalin Susztak,et al. The Evolving Understanding of the Contribution of Lipid Metabolism to Diabetic Kidney Disease , 2015, Current Diabetes Reports.
[9] N. Vaziri,et al. Lipidomics: new insight into kidney disease. , 2015, Advances in clinical chemistry.
[10] Kerri J Grove,et al. Diabetic nephropathy induces alterations in the glomerular and tubule lipid profiles1[S] , 2014, Journal of Lipid Research.
[11] S. Nie,et al. The association between lipid metabolism gene polymorphisms and nephropathy in type 2 diabetes: a meta-analysis , 2014, International Urology and Nephrology.
[12] A. Tokumura,et al. Presence of bioactive lysophosphatidic acid in renal effluent of rats with unilateral ureteral obstruction. , 2011, Life sciences.
[13] Julie Klein,et al. Lysophosphatidic acid-1-receptor targeting agents for fibrosis , 2011, Expert opinion on investigational drugs.
[14] S. Hadjadj,et al. Prognostic Value of the Insertion/Deletion Polymorphism of the ACE Gene in Type 2 Diabetic Subjects: Results From the Non-Insulin-Dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR), Diabete de type 2, Nephropathie et Genetique (DIAB2NEP , 2008, Diabetes Care.
[15] S. Hadjadj,et al. Prognostic Value of the Insertion/ Deletion polymorphism of Angiotensin I Converting Enzyme gene in type 2 diabetic subjects: results from the DIABHYCAR, DIAB2NEPHROGENE & SURDIAGENE studies. , 2008 .
[16] J. Chun,et al. LPA1 receptor activation promotes renal interstitial fibrosis. , 2007, Journal of the American Society of Nephrology : JASN.
[17] Y. Yatomi,et al. Lysophospholipase D activity exists in the urine to catalyse the formation of lysophosphatidic acid. , 2006, Nephrology, Dialysis and Transplantation.
[18] A. Cases,et al. Dyslipidemia and the progression of renal disease in chronic renal failure patients. , 2005, Kidney international. Supplement.
[19] J. Pfeilschifter,et al. Enhanced expression of group IIA secreted phospholipase A2 by elevated glucose levels in cytokine-stimulated rat mesangial cells and in kidneys of diabetic rats. , 2005, Clinical nephrology.
[20] B. Kasiske,et al. Effect of lipid reduction on the progression of renal disease: a meta-analysis. , 2001, Kidney international.
[21] M. Lagarde,et al. Characterization of plasma unsaturated lysophosphatidylcholines in human and rat. , 2000, The Biochemical journal.
[22] K. Hruska,et al. Stimulation of phosphatidylcholine biosynthesis in diabetic hypertrophic kidneys. , 1987, Endocrinology.